Publications

Getty Images publications

Publications

Featured Publications

Publications

Filter:

Filter results Close
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
  • expanded
Mark Holodniy
Journal Articles

Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States

Cora L. Bernard, Margaret L. Brandeau, Keith Humphreys, Eran Bendavid, Mark Holodniy, Christopher Weyant, Douglas K. Owens, Jeremy Goldhaber-Fiebert
Annals of Internal Medicine, 2016 July 5, 2016

Background: The total population health benefits and costs of HIV preexposure prophylaxis (PrEP) for people who inject drugs (PWID) in the United States are unclear.

Objective: To evaluate the cost-effectiveness and optimal delivery conditions of PrEP for PWID.

Design: Empirically calibrated dynamic compartmental model.

Data Sources: Published literature and expert opinion.

Target Population: Adult U.S. PWID.

Time Horizon: 20 years and lifetime.

Show body
Journal Articles

Risk of Cardiovascular Events Associated With Current Exposure to HIV Antiretroviral Therapies in a US Veteran Population

Manisha Desai, Vilija Joyce, Eran Bendavid, Richard A. Olshen, Mark A. Hlatky, Adam Chow, Mark Holodniy, Paul Barnett, Douglas K. Owens
Clinical Infectious Diseases, 2015 August 1, 2015

Background. To characterize the association of antiretroviral drug combinations on risk of cardiovascular events.

Show body
Journal Articles

New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis

Shan Liu, Lauren E. Cipriano, Mark Holodniy, Douglas K. Owens, Jeremy Goldhaber-Fiebert
Annals of Internal Medicine, 2012 February 21, 2012

Background: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of standard therapy, but they are costly. A genetic assay may identify patients most likely to benefit from this treatment advance.

Objective: To assess the cost-effectiveness of new protease inhibitors and an interleukin (IL)–28B genotyping assay for treating chronic hepatitis C virus.

Show body
Journal Articles

Determinants of the cost of health services used by veterans with HIV

Barnett PG, Chow A, Vilija Joyce, Bayoumi AM, Griffin SC, Nosyk B, Mark Holodniy, Brown ST, Sculpher M, Anis AH, Douglas K. Owens
Medical Care, 2011 December 31, 2011

BACKGROUND:

The effect of adherence, treatment failure, and comorbidities on the cost of HIV care is not well understood.

OBJECTIVE:

To characterize the cost of HIV care including combination antiretroviral treatment (ART).

RESEARCH DESIGN:

Observational study of administrative data.

SUBJECTS:

Total 1896 randomly selected HIV-infected patients and 288 trial participants with multidrug-resistant HIV seen at the US Veterans Health Administration (VHA).

MEASURES:

Comorbidities, cost, pharmacy, and laboratory data.

Show body
Journal Articles

One-year outcomes of community-acquired and health care-associated pneumonia in the Veterans Affairs Health Care System

Hsu JL, Siroka AM, Mark W. Smith, Mark Holodniy, Meduri GU
International Journal of Infectious Disease, 2011 December 31, 2011

Abstract

BACKGROUND:

While studies have demonstrated higher medium-term mortality for community-acquired pneumonia (CAP), mortality and costs have not been characterized for healthcare-associated pneumonia (HCAP) over a 1-year period.

Show body
Journal Articles

Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-related Quality of Life in Patients with Advanced HIV

Vilija Joyce, Paul G. Barnett, Adam Chow, Ahmed M. Bayoumi, Susan C. Griffin, Huiying Sun, Mark Holodniy, Sheldon T. Brown, Tassos C. Kyriakides, D. William Cameron, Mike Youle, Mark Sculpher, Aslam H. Anis, Douglas K. Owens
Medical Decision Making, 2011 March 7, 2011

Background. The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown.

Objective. To assess the impact of temporary treatment interruption and intensification of ART on HRQoL.

Design. A 2 x 2 factorial open label randomized controlled trial.

Setting. Hospitals in the United States, Canada, and the United Kingdom.

Show body
Journal Articles

Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-drug Resistant HIV Infection from the OPTIMA trial

Mark Holodniy, Sheldon T. Brown, D. William Cameron, Tassos C. Kyriakides, Brian Angus, Abdel Babiker Abdel Babiker, Joel Singer, Douglas K. Owens, Aslam Anis, Ruth Goodall, Fleur Hudson, Mirek Piaseczny, John Russo, Martin Schechter, Lawrence Deyton, Janet Darbyshire
PLoS ONE, 2011 March 1, 2011

Background Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting.

Show body
Journal Articles

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.

Anis AH, Nosyk B, Sun HSun H, Guh DPGuh DP, Bansback NBansback N, Li X, Paul G. Barnett, Vilija Joyce, Swanson KM, Kyriakides TC, Mark Holodniy, Cameron DW, Brown ST, OPTIMA TEAM
JAIDS, 2009 December 31, 2009
Show body
Journal Articles

The Concurrent Validity and Responsiveness of the Health Utilities Index (HUI 3) Among Patients with Advanced HIV/AIDS

Nosyk B, Sun H, Bansback N, Guh DP, Li X, Paul G. Barnett, Bayoumi A, Griffin S, Vilija Joyce, Mark Holodniy, Douglas Owens, Anis AH
Quality of Life Research, 2009 June 27, 2009

Objectives To assess the concurrent validity and responsiveness of the Health Utility Index 3 (HUI3) in patients with advanced HIV/AIDS, and to determine the responsiveness of this measure, the MOS-HIV and EQ-5D to HIV-related clinical events.

Show body
Journal Articles

Health-related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease

Vilija Joyce, Paul G. Barnett, Bayoumi AM, Griffin SC, Kyriakides TC, Wei Yu, Vandana Sundaram, Mark Holodniy, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Douglas Owens
Journal of Acquired Immune Deficiency Syndromes, 2009 January 1, 2009

OBJECTIVE: To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables. DESIGN: Cross-sectional study.

SETTING: Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada, and 8 hospitals in the United Kingdom.

PATIENTS: Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial.

Show body
Journal Articles

Frequency of HIV Screening in the Veterans Health Administrations: Implications for Early Diagnosis of HIV Infection

Valdiserri R, Rodriguez F, Mark Holodniy
AIDS Education and Prevention, 2008 December 31, 2008

We evaluated the frequency of HIV testing across the Department of Veterans Affairs (VA), the largest provider of HIV care in the United States. An electronic survey was used to determine the volume and location of HIV screening, confirmatory testing, rapid testing and laboratory consent policies in VA medical centers between October 1, 2005, and September 30, 2006. One hundred thirty-five VA laboratories reported that 112,033 HIV screening tests were performed (81% outpatients vs. 19% inpatients, p<.0001). Overall HIV prevalence was 1.49% (1.62% in inpatients vs.

Show body
Journal Articles

Cost Effectiveness of HIV Screening in the Elderly

Gillian D. Sanders, Bayoumi AM, Mark Holodniy, Douglas K. Owens
Ann Intern Med, 2008 December 31, 2008

Although HIV infection is more prevalent in people younger than age 45 years, a substantial number of infections occur in older persons. Recent guidelines recommend HIV screening in patients age 13 to 64 years. The cost-effectiveness of HIV screening in patients age 55 to 75 years is uncertain. OBJECTIVE: To examine the costs and benefits of HIV screening in patients age 55 to 75 years. DESIGN: Markov model. DATA SOURCES: Derived from the literature. TARGET POPULATION: Patients age 55 to 75 years with unknown HIV status. TIME HORIZON: Lifetime. PERSPECTIVE: Societal.

Show body
Journal Articles

The Prevalence of HIV-1 Infection Amoung Inpatients and Outpatients in Department of Veterans Affairs Health Care Systems: Implications for Screening Programs for HIV

Douglas K. Owens, Vandana Sundaram, Lazzeroni LC, Douglass LR, Gillian D. Sanders, Taylor K, VanGroningen R, Shadle VM, McWhorter VCMcWhorter VC, Agoncillo TAgoncillo T, Haren N, Nyland J, Tempio P, Khayr W, Dietzen D, Jensen P, Simberkoff MS, Bozzette SA, Mark Holodniy
Am J Public Health, 2007 December 31, 2007

OBJECTIVES: We sought to determine the prevalence of HIV in both inpatient and outpatient settings in 6 Department of Veterans Affairs (VA) health care sites. METHODS: We collected demographic data and data on comorbid conditions and then conducted blinded, anonymous HIV testing. We conducted a multivariate analysis to determine predictors of HIV infection. RESULTS: We tested 4500 outpatient blood specimens and 4205 inpatient blood specimens; 326 (3.7%) patients tested positive for HIV. Inpatient HIV prevalence ranged from 1.2% to 6.9%; outpatient HIV prevalence ranged from 0.9% to 8.9%.

Show body
Journal Articles

A Systematic Review of Cost-Utility Analyses in HIV/AIDS

Hornberger J, Mark Holodniy, Robertus K, Winnike M, Gibson M, Verhulst E
Medical Decision Making, 2007 December 31, 2007

OBJECTIVES: To determine whether gaps exist in published cost-utility analyses as measured by their coverage of topics addressed in current HIV guidelines from the Department of Health and Human Services (DHHS).

DESIGN: A systematic review of US-based cost-effectiveness analyses of HIV/AIDS prevention and management strategies, based on original, published research.

Show body
Journal Articles

Relationship between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naive, HIV-1 Infected U.S. Veterans

Mark Holodniy, Hornberg J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L
JAIDS, 2007 December 31, 2007

To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection. DESIGN: Retrospective cohort study. METHODS: We evaluated ARV prescribing patterns among ARV treatment-naive veterans who were receiving care within the US Department of Veterans Affairs (VA) from 1992 through 2004 in comparison to evolving adult HIV-1 treatment guidelines. RESULTS: A total of 15,934 patients initiated ARV treatment.

Show body